Pertuzumab,Trastuzumab

Pertuzumab and trastuzumab are humanized monoclonal antibodies used together to treat human epidermal growth factor receptor 2 (HER2)-positive breast cancer. HER2 is a protein involved in cell growth and survival that can be overexpressed in certain breast cancers, contributing to more aggressive tumour behaviour. Both medicines target HER2, but they bind to different regions of the receptor and inhibit its signalling through complementary mechanisms.

Trastuzumab binds to the extracellular domain IV of HER2, while pertuzumab binds to domain II and interferes with HER2 pairing with other receptors, particularly HER3. Together, they help suppress tumour growth and promote immune-mediated destruction of cancer cells. Their combination is commonly used with chemotherapy in appropriate patients with early-stage or metastatic HER2-positive breast cancer.

The medicines can be administered separately by intravenous infusion or, where an approved fixed-dose formulation is available, together as a subcutaneous injection containing pertuzumab, trastuzumab, and hyaluronidase. The formulation, route, and dosing schedule must not be interchanged without following the applicable prescribing information. Treatment selection depends on HER2 test results, disease stage, previous treatment, cardiac function, and the patient's overall clinical condition.

Trastuzumab was developed as a targeted treatment against HER2 and received initial US Food and Drug Administration (FDA) approval in 1998 for HER2-overexpressing metastatic breast cancer. Pertuzumab was subsequently developed to block a different region of HER2 and received FDA approval in 2012 for use with trastuzumab and docetaxel in selected patients with HER2-positive metastatic breast cancer. The combination was later incorporated into treatment regimens for selected patients with early-stage disease, including neoadjuvant treatment before surgery and adjuvant treatment after surgery.

The fixed-dose subcutaneous combination of pertuzumab, trastuzumab, and hyaluronidase, marketed as Phesgo in certain jurisdictions, received FDA approval on 29 June 2020 and European Medicines Agency (EMA) authorisation on 21 December 2020. Its regulatory evaluation included the FeDeriCa clinical trial, which compared the subcutaneous combination with intravenous pertuzumab and trastuzumab in patients with HER2-positive early breast cancer. The fixed-dose product is not simply interchangeable with the individual intravenous medicines; the approved formulation and local prescribing information determine its appropriate use. Approval status and authorised indications may vary by country, including India.

Pertuzumab and trastuzumab are used together in selected adults with confirmed HER2-positive breast cancer. In early-stage disease, they may be combined with chemotherapy before surgery when the tumour or disease characteristics meet the relevant criteria, or after surgery in patients at increased risk of recurrence. Neoadjuvant treatment aims to reduce tumour burden and assess response, while adjuvant treatment aims to reduce the risk of cancer returning.

In metastatic or locally recurrent unresectable HER2-positive breast cancer, pertuzumab and trastuzumab may be combined with docetaxel in patients who meet the applicable treatment criteria, including relevant requirements concerning previous therapy. Other treatment combinations or sequencing decisions may be appropriate according to disease setting, previous treatment, and current guidelines.

HER2 status must be established using validated testing of tumour tissue. These medicines are not indicated for every type of breast cancer, and HER2-negative disease generally requires a different treatment approach. The exact indication depends on the individual medicine or fixed-dose formulation, local regulatory approval, disease stage, and the complete treatment regimen.

Pertuzumab and trastuzumab are administered under the supervision of healthcare professionals experienced in cancer treatment. When given separately, both medicines are administered by intravenous infusion using their respective prescribing instructions. For the intravenous combination, pertuzumab is generally initiated with a loading dose of 840 mg, followed by 420 mg every three weeks; trastuzumab dosing depends on the selected weekly or three-weekly regimen. When the fixed-dose subcutaneous combination containing pertuzumab, trastuzumab, and hyaluronidase is used, the usual initial dose contains pertuzumab 1,200 mg and trastuzumab 600 mg, followed by pertuzumab 600 mg and trastuzumab 600 mg every three weeks. These schedules are formulation-specific and must not be interchanged.

Treatment duration depends on whether therapy is being used before surgery, after surgery, or for metastatic disease. In early breast cancer, HER2-targeted treatment commonly continues to complete an approximately one-year course when clinically appropriate, subject to the prescribed regimen, treatment response, and tolerability. In metastatic disease, treatment may continue until progression or unacceptable toxicity. Cardiac function, treatment tolerance, and infusion or injection reactions should be assessed throughout therapy. Dosing must be individualised by the treating oncology team.

Common adverse effects associated with pertuzumab and trastuzumab combination therapy include diarrhoea, nausea, vomiting, fatigue, hair loss, rash, reduced appetite, muscle or joint discomfort, and infusion-related or injection-site reactions. When chemotherapy is administered alongside these medicines, additional effects such as anaemia, neutropenia, and other changes in blood cell counts may occur. The frequency and severity of symptoms vary according to the treatment regimen, the patient's health, and the stage of disease.

Subcutaneous administration may cause local reactions, including pain, redness, swelling, or discomfort at the injection site. Diarrhoea and nausea can often be managed with supportive treatment prescribed by the clinical team. Patients should report persistent symptoms, dehydration, fever, or any adverse effect that interferes with daily activities. Supportive care, appropriate laboratory monitoring, and timely clinical assessment can help maintain treatment tolerability.

A major safety concern with pertuzumab and trastuzumab is cardiac dysfunction, including reduced left ventricular ejection fraction and congestive heart failure. The risk is particularly important in patients with pre-existing cardiac disease, previous exposure to anthracycline chemotherapy, or prior treatment that may affect heart function. Baseline cardiac assessment and periodic monitoring are necessary, and treatment may need to be withheld or discontinued if clinically significant cardiac deterioration occurs.

Other serious risks include severe infusion-related or hypersensitivity reactions, anaphylaxis, and serious pulmonary complications. Neutropenia and febrile neutropenia may occur, particularly when these medicines are combined with chemotherapy. Embryo-fetal toxicity is also an important warning: exposure during pregnancy may cause fetal harm, and pregnancy status and reproductive risks should be discussed before treatment. Severe reactions require prompt medical assessment, and treatment interruption or discontinuation should follow the relevant prescribing information.

Before starting treatment, clinicians should confirm HER2 positivity using validated testing and assess cardiac function, medical history, previous anticancer therapies, and current medications. Pregnancy status should be evaluated when relevant, and patients should receive counselling about contraception and potential fetal risks. Patients with reduced cardiac function or significant cardiac disease may require additional assessment and closer monitoring.

Classic metabolic drug interactions are generally less prominent with monoclonal antibodies than with many small-molecule medicines because these antibodies are not primarily eliminated through conventional hepatic drug-metabolising enzymes. However, interactions involving the overall treatment regimen remain clinically important. Chemotherapy agents, particularly anthracyclines, may increase cardiac risk, and other anticancer medicines may contribute to overlapping toxicities. Live vaccines and vaccination timing should be discussed with the oncology team, especially during concurrent immunosuppressive chemotherapy. Patients should disclose all prescription medicines, over-the-counter products, and supplements before treatment.

Confirm the patient's HER2 status and disease stage before initiating therapy, and verify that the selected formulation is authorised for the intended indication. Document baseline left ventricular ejection fraction and establish a cardiac monitoring schedule consistent with the applicable prescribing information and clinical circumstances. Review previous anthracycline exposure, cardiovascular risk factors, pregnancy considerations, and concurrent chemotherapy before each treatment cycle.

For intravenous administration, follow the individual product's infusion instructions and observe the patient for infusion-related reactions. For the fixed-dose subcutaneous formulation, use the specified loading and maintenance schedules, administer the medicine only by the authorised route and site, and observe patients for hypersensitivity or administration-related reactions. Do not substitute the fixed-dose combination for the individual intravenous products on a milligram-for-milligram basis. Monitor blood counts and other laboratory parameters according to the accompanying chemotherapy regimen, assess diarrhoea and other treatment-related symptoms, and promptly investigate new breathlessness, oedema, or other symptoms suggestive of cardiac dysfunction. Clear communication among oncologists, pharmacists, nurses, and patients supports safe administration and continuity of care.